1. Насонов Е.Л. Антифосфолипидный синдром. М: Литтера, 2004.
2. Myakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006; 4: 295–306.
3. Решетняк Т.М., Середавкина Н.В., Насонов Е.Н. Кардиоваскулярные аспекты антифосфолипидного синдрома. Клиническая Медицина, 2008; 9: 4–12.
4. Doria A, Sarzi-Puttini P. Heart, rheumatism and autoimmunity: an old intriguing link (editorial). Lupus. 2005; 14: 643–5.
5. Asherson RA, Tikly M, Staub H et al. Infective endocarditis, rheumatoid factor, and anticardiolipin antibodies. Ann Rheum Dis 1990; 49: 107–8.
6. Ford PM, Ford SE, Lillicrap DP. Association of lupus anticoagulant with severe valvular heart disease in systemic lupus erythematosus. J Rheumatol 1988; 15: 597–600.
7. Chartash EK, Lans DM, Paget SA et al. Aortic insuffiency and mitral regurgitation in patients with systemic lupus erythematosus and antiphospholipid syndrome. Am J Med 1989; 86: 407–12.
8. Ziporen L, Golberg N, Arod M et al. Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings inderformed heart valve. Lupus 1996; 5: 196–205.
9. Nesher G, Ilany J, Rosenmsnn D et al. Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment. Semin. Arthritis. Rheum 1997; 27: 27–35.
10. Hojnik M, George J, Ziporen L et al. Heart valve involvement (Libman-Sacs endocarditis) in the antiphospholipid syndrome. Circulation 1996; 93: 1579–87.
11. Khamashta MA, Cervera R, Asherson RA et al. Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet 1990; 335: 1541–4.
12. Nihoyannopoulos P, Gomez P, Joshi M et al. Cardiac abnormalities in systemic lupus erythematosus. Association with raised anticardiolipin antibodies. Circulation 1990; 82: 369–75.
13. Roldan CA, Shively BK, Lau CC et al. Systemic lupus erythematosus disease by transesofagealechocardiography and the role of antiphospholipid antibodies. J Am Coll Cardiol 1992; 20: 1127–34.
14. Vianna IL, Khamashta MA, Ordi-Ros J et al. Comparision of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Am J Med 1994; 96: 3–9.
15. Turiell M, Muzzupappa S, Gottardi B et al. Evalution of cardiac abnormalities and embolic sources in primery antiphospholipid syndrome by transesophageal echocardiography. Lupus 2000; 9: 406–12.
16. Espinola-Zavaleta N, Vargas-Barron J, Colmenares-Galvis T e t al. Echocardiagraphic evalution of patients with primary antiphospholipid syndrome. Am Heart J 1999; 137: 973–9.
17. Gabriel F, Alcini E, Di Prima MA et al. Cardiac valve involvement in systemic lupus erythematosus and primary antiphospholipid syndrome: lack of correlation with antiphospholipid antibodies. Int J Cardiol 1995; 51: 117–26.
18. Leung W-H, Wong K-L, Lau C-P et al. Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus. Am J Med 1990; 89: 411–9.
19. Решетняк Т.М., Котельникова Г.П., Фомичева О.А. и др. Кардиологические аспекты антифосфолипидного синдрома. Часть 1. Клапанные поражения сердца при первичном и вторичном антифосфолипидном синдроме и системной красной волчанке. Кардиология 2002; 8: 38–43.
20. Cervera R, Font J, Ingelmo M et al. Cardiac manifestations in the antiphospholipid syndrome. Eds. R.A.Asherson, R.Cervera, J.C.Piette, Y.Shoenfeld. The antiphospholipid syndrome. New York – London – Tokyo, PRC Press Boca Raton, 1996; 151–60.
21. Barbut D, Borer JS, Gharavi A et al. Prevalence of anticardiolipin antibody in isolated mitral or aortic regurgitation, or both, and possible relation to cerebral ischemic events. Am J Cardiol 1992; 70: 901–5.
22. Myers GJ, Hirsch GM Double valve replacement in a patients with anticardiolipin antibody syndrome. Perfusion 1999; 14: 397–401
23. Brownstein L, Bartholomew TP, Silver DG, Berry CM A case report of mitral valve replacement in patients with lupus antibody syndrome. Perfuaion 2003; 18: 373–6.
24. Tenedios F, Erkan D, Lockshin MD Cardiac involvement in the antiphospholipid syndrome. Lupus, 2005; 14(9): 691–6
25. Bercun Y, Elami A, Meir K et al. Increased morbidity and mortality in patients with antiphospholipid syndrome undergoing valve replacement surgery. J Thoracic Cardiovasc Sur 2004; 127: 414–20.
26. Figueroa F, Berrios X, Guttierez M et al. Anticardiolipin antibodies in acute rheumatic fever. J Rheumatol 1992; 19: 1175–80.
27. Narin N, Kutukcler N, Narin F et al. Anticardiolipin antibodies in acute rheumatic fever and chronic rheumatic heart disease: is there a significant association? Clin Exp Rheumatol 1996; 14: 567–9.
28. Diniz REAS, Goldenberg J, Andrade LEC et al. Antiphospholipid antibodies in Rheumatic fever chorea. J Rheumatol 1994; 21: 1367.
29. Illaraza H, Marquez MF, Alcocer A et al. Anticardiolipin antibodies are not associated with rheumatic heart disease. Lupus 2001; 10: 873–5.
30. Blank M, Aro-Maor A, Shoenfeld Y From rheumatic fever to Libman-Sacks endocarditis: is there any possible pathogenetic link? Lupus 2005; 14: 697–701.
31. Bick RL, Ismail Y, Baker WF et al. Coagulation abnormalities in patients with precocious coronary artery bypass grafting and precutaneus transcoronary angioplasty. Semin. J Thromb Hemost 1993; 19: 411–7.
32. Gavaghan TP, Krilis SA, Daggard GE et al. Anticardiolipin antibodies and occlusion of coronary bypass grafts. Lancet 1987; 2: 977–8.
33. Krinic-Barrie SO, O'Connor CR, Looney SW et al. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis. Arch Intern Med 1997; 157: 2101–8.
34. Решетняк Т.М., Алекберова З.С., Александрова Е.Н. и др. Клинические аспекты антифосфолипидного синдрома. Вестник РАМН 2003; 7: 31–4.
35. Vaarala O, Manttari M, Manninen V et al. Anticardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995; 91(1): 23–7.
36. Sletness KE, Smith P, Abdelnoor M et al. Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke. Lancet 1992; 339: 451–3.
37. De Caterina R, d'Ascanio A, Mazzone A et al. Prevalence of anticardiolipin antibodies in coronary artery disease. Am J Cardiol 1990; 65: 922–3.
38. Diaz MN, Becker RC. Anticardiolipin antibodies in patients with unstable angina. Cardiology 1994; 84: 380–4.
39. Farsi A, Domeneghetti MP, Fedi S et al. High prevalence of anti-beta2-glycoprotein I antibodies in patients with ischemic heart disease. Autoimmunity 1999; 30: 93–8.
40. Veres K, Lakos G, Kereneyi A et al. Antiphospholipid antibodies in acute coronary syndrome. Lupus 2004; 13: 423–7.
41. Ciocca R, Choi J, Graham A. Antiphospholipid antibodies lead to increased risk in cardiovascular surgery. Am J Surg 1995; 170: 198–200.
42. Jankowski M, Didek D, Dubiel JS et al. Successful coronary stent implantation in a patient with primary antiphospholipid syndrome. Blood Coagul Fibrinolysis 1998; 9: 753–6.
43. Umesan CV, Kapoor A, Nityanand S et al. Recurrent acute coronary events in patients with primary antiphospholipid syndrome: successful management with intracoronary stenting. Int J Cardiol 1999; 71: 99–102.
44. Lagana B, Baratta L, Tubani L et al. Myocardial infarction with normal coronary arteries in patient with primary antiphospholipid syndrome. Case report and literature review. Angiology 2001; 52: 785–8.
45. Asherson RA, Cervera R. Catastrophic antiphospholipid syndrome. Cur Rheum Reports 2003; 5: 395–400.
46. Насонова В.А, Решетняк Т.М., Раденска-Лоповок С.Г. и др. Адекватность терапии и сотрудничество больного – два неотъемлемых компонента благополучного исхода системной красной волчанки (клинический разбор). Врач. 2005; 8: 13–7.
47. Решетняк Т.М., Александрова Е.Н., Штивельбанд И.Б. и др. Катастрофический антифосфолипидный синдром: диагностика и терапия. Тер. архив 2005; 5: 41–6.
48. Gertner E, Leatherman JW. Intracardiac mural thrombosis mimicking myxoma in the antiphospholipid syndrome. J Rheumatol 1992; 19: 1293–8.
49. The Antiphospholipid Antibodies in Stroke Study Group. Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischemia. Stroke 1990; 21: 1268–73.
50. Насонов Е.Л. Проблемы атеротромбоза в ревматологии. Вестник РАМН. 2003; 7: 6–11.
51. Кондратьева Л.В., Роденска-Лаповок С.Г., Решетняк Т.М. и др. Инфаркт миокарда и геморрагический альвеолит при системной красной волчанке. Консилиум. 2007; 9 (2): 17–21.
52. Medina G, Casaos D, Jara LJ et al. Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome. Ann. Rheum. Dis 2003; 62(7): 607–10.
53. Jimenez S, Garcia-Criado MA, Tassies D et al. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome Rheumatology (Oxford) 2005; 44(6): 756–61.
54. Ames PR, Margarita A, Sokoll KB et al. Premature atherosclerosis in primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis 2005; 64(2): 315–7.
55. Ames PR, Margarita A, Delgado Alves J et al. Anticardiolipin antibody titre and plasma homocysteine level independently predict intima-media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus 2002; 11(4): 208–14.
56. Maslowski L, McBane R, Alexewicz P, Wysokinski WE Antiphospholipid antibodies in thromboangiitis obliterans. Vascular Med 2002; 7: 259–64.
57. Ames PR, Delgado Alves J, Lopes LR et al. Antibodies against beta2-glycoprotein I complexed with an oxidised lipoprotein relate to intima thickening of carotid arteries in primary antiphospholipid syndrome. Clin Dev Immunol 2006; 3(1): 1–9.
58. Der H, Kerekes G, Veres K et al. Impaired endothelial function and increased carotid intima-media thickness in association with elevated von Willebrand antigen level in primary antiphospholipid syndrome. Lupus 2007; 16(7): 497–503.
59. Stalc M, Poredos P, Peternel P et al. Endothelial function is impaired in patients with primary antiphospholipid syndrome. Thromb Res 2006; 118(4): 455–61.
60. Falaschi F., Ravelli A., Martignoni A. et al. Nephrotic-range proteinuria, the major risk factor for early atherosclerosis in juvenile-onset systemic lupus erythematosus. Arthritis Rheum 2000; 43: 1405–9.
61. Becarevic M., Andrejevic S., Miljic P et al. Serum lipids and anti-oxidized LDL antibodies in primary antiphospholipid syndrome. Clin Exp Rheumatol 2007; 25(3): 361–6.
62. Margarita A, Batuca J, Scenna G et al. Subclinical atherosclerosis in primary antiphospholipid syndrome. Ann N Y Acad Sci 2007; 1108: 475–80.
63. Bilora F, Boccioletti V, Girolami B et al. Are antiphospholipid antibodies an independent risk factor for atheroslerosis? Clin Appl Thromb Hemost 2002; 8: 103–113.

Т.М.Решетняк, Н.В.Середавкина, Е.Л.Насонов